Will REMS Delay Generics? Dr. Reddy’s Revlimid Petition May Help Determine Answer
This article was originally published in PharmAsia News
Executive Summary
Dr. Reddy's is urging U.S. FDA to start now to define a policy that assures that restricted distribution programs and other types of Risk Evaluation and Mitigation Strategies won't be used to block generic drug approvals